mRNA-Based Vaccines Are Highly Immunogenic and Confer Protection in the Gnotobiotic Pig Model of Human Rotavirus Diarrhea

Casey Hensley,Sandro Roier,Peng Zhou,Sofia Schnur,Charlotte Nyblade,Viviana Parreno,Annie Frazier,Maggie Frazier,Kelsey Kiley,Samantha O’Brien,Yu Liang,Bryan T. Mayer,Ruizhe Wu,Celia Mahoney,Monica M. McNeal,Benjamin Petsch,Susanne Rauch,Lijuan Yuan

DOI: https://doi.org/10.3390/vaccines12030260

2024-03-02

Vaccines

Abstract:Human rotavirus (HRV) is still a leading cause of severe dehydrating gastroenteritis globally, particularly in infants and children. Previously, we demonstrated the immunogenicity of mRNA-based HRV vaccine candidates expressing the viral spike protein VP8* in rodent models. In the present study, we assessed the immunogenicity and protective efficacy of two mRNA-based HRV trivalent vaccine candidates, encoding VP8* of the genotypes P[8], P[6], or P[4], in the gnotobiotic (Gn) pig model of Wa (G1P[8]) HRV infection and diarrhea. Vaccines either encoded VP8* alone fused to the universal T-cell epitope P2 (P2-VP8*) or expressed P2-VP8* as a fusion protein with lumazine synthase (LS-P2-VP8*) to allow the formation and secretion of protein particles that present VP8* on their surface. Gn pigs were randomly assigned into groups and immunized three times with either P2-VP8* (30 μg) or LS-P2-VP8* (30 μg or 12 μg). A trivalent alum-adjuvanted P2-VP8* protein vaccine or an LNP-formulated irrelevant mRNA vaccine served as the positive and negative control, respectively. Upon challenge with virulent Wa HRV, a significantly shortened duration and decreased severity of diarrhea and significant protection from virus shedding was induced by both mRNA vaccine candidates compared to the negative control. Both LS-P2-VP8* doses induced significantly higher VP8*-specific IgG antibody titers in the serum after immunizations than the negative as well as the protein control. The P[8] VP8*-specific IgG antibody-secreting cells in the ileum, spleen, and blood seven days post-challenge, as well as VP8*-specific IFN-γ-producing T-cell numbers increased in all three mRNA-vaccinated pig groups compared to the negative control. Overall, there was a clear tendency towards improved responses in LS-P2-VP8* compared to the P2-VP8*mRNA vaccine. The demonstrated strong humoral immune responses, priming for effector T cells, and the significant reduction of viral shedding and duration of diarrhea in Gn pigs provide a promising proof of concept and may provide guidance for the further development of mRNA-based rotavirus vaccines.

immunology,medicine, research & experimental

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to evaluate the immunogenicity and protective efficacy of mRNA - based rotavirus vaccines in human rotavirus (HRV) infection and diarrhea in the germ - free pig model. Specifically, the researchers wanted to verify the following two main issues:

1. **Can mRNA vaccines provide protection against HRV infection in the germ - free pig model, and how does their efficacy compare with that of protein vaccines?**
- The study evaluated the effectiveness and immune response of mRNA vaccines by comparing the performance of mRNA vaccines and traditional protein vaccines in the germ - free pig model.

2. **Among the two mRNA vaccine candidates (P2 - VP8* and LS - P2 - VP8*), which one can provide better protection and immunogenicity?**
- The researchers tested two different mRNA vaccine designs. Among them, P2 - VP8* is an mRNA vaccine that fuses the universal T - cell epitope P2 and the rotavirus VP8* protein, while LS - P2 - VP8* further fuses luciferase synthase (LS) from thermophilic bacteria on this basis to promote the formation of nanoparticles, thereby presenting the VP8* protein more effectively.

To answer these questions, the researchers used the germ - free pig model, which can simulate the human immune response to rotavirus infection and is particularly valuable in evaluating vaccine - induced immune responses and protection effects. The study comprehensively evaluated the immunogenicity and protection effects of mRNA vaccines through multiple immunizations, virus challenge tests, and detailed immunological detections.